ReviewAdvances in experimental medicine and biology2026
Precision Medicine Bioethics and AI Ethics: The Case of Rare Diseases.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine leverages genomics, metabolomics, and biomedical data sciences to develop targeted treatments based on individual genetic, environmental, and lifestyle factors. While standardized treatments work for some conditions, many require a personalized approach to improve therapeutic outcomes. The integration of artificial intelligence (AI) and big data analytics enhances precision medicine by enabling predictive models and individualized treatment plans. A key application of precision medicine is in rare disease diagnosis and treatment, where AI-driven methodologies improve diagnostic accuracy and therapeutic development. Multidisciplinary collaboration among researchers, healthcare professionals, and patient advocacy groups is essential to advancing care and ensuring equitable access to innovative treatments. Despite these advancements, ethical concerns regarding AI in precision medicine remain a challenge. Addressing these issues requires transdisciplinary research involving medical practitioners, ethicists, and data scientists to develop robust validation frameworks and certification methodologies. This paper explores the ethical implications of AI in precision medicine and rare disease treatment, emphasizing the need for responsible algorithm governance. The findings aim to provide a foundation for future research on integrating ethical considerations into AI-driven healthcare, ensuring safe, transparent, and equitable medical innovations.
Indexed as
Identifiers
41479080What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.